Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Jiangzhuo Qinggan Prescription and Irbesartan in the Treatment of Essential Hypertension(Hepatogastric Damp-heat)Clinical Study (JZQG)

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified March 2010 by Guang'anmen Hospital of China Academy of Chinese Medical Sciences.
Recruitment status was:  Not yet recruiting
Information provided by:
Guang'anmen Hospital of China Academy of Chinese Medical Sciences Identifier:
First received: March 8, 2010
Last updated: March 15, 2010
Last verified: March 2010
Jangzhuo Qinggan prescription and irbesartan in the treatment of essential hypertension(Hepatogastric Damp-heat), randomized, parallel-controlled, multi-center clinical study.

Metabolic Syndrome

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Prospective
Official Title: Jiangzhuo Qinggan Prescription and Irbesartan in the Treatment of Essential Hypertension(Hepatogastric Damp-heat), Randomized, Parallel-controlled, Multi-center Clinical Study

Resource links provided by NLM:

Further study details as provided by Guang'anmen Hospital of China Academy of Chinese Medical Sciences:

Estimated Enrollment: 240
Study Start Date: March 2010
Estimated Study Completion Date: August 2010
Estimated Primary Completion Date: July 2010 (Final data collection date for primary outcome measure)
the group of Jiangzhuo Qinggan prescription
the group of irbesartan

Detailed Description:
Charged by the five research centers in line with traditional Chinese medicine hepatogastric Damp-heat syndrome 240 cases have hypertension, and overweight, as well as blood lipid disorders or diabetes were randomly divided into Chinese herbal compound Jiangzhuo Qinggan prescription group and western medicine irbesartan group.The treatment groups were compared 4-week step-down and regulation of blood lipids, blood sugar effect.

Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Combined metabolic syndrome in patients with essential hypertension

Inclusion Criteria:

  1. Consistent with diagnosed hypertension, blood pressure, for 1-2 grade.
  2. Aged 18-65 years old.
  3. Body mass index (BMI) ≥ 24kg/m2, but <35 kg/m2.
  4. Waist circumference ≥ 85cm (male) or waist circumference ≥ 80cm (women).
  5. Comply with any of the following 3 : triglyceride (TG) elevated levels of:> 150mg/dl (1.7mmol / l), or has received appropriate treatment; high-density lipoprotein - cholesterol (HDL-C) levels reduced: Men <40mg/dl (0.9mmol / l), women <50mg/dl (1.1mmol / l), or has received appropriate treatment; fasting plasma glucose (FPG) increased: FPG ≥ 100mg/dl (5.6mmol / l ), or previously diagnosed type 2 diabetes or have received appropriate treatment.
  6. Hepatogastric Damp-heat syndrome differentiation.
  7. To sign informed consent.

Exclusion Criteria:

  1. Has been used to control lipids, blood sugar drugs, but use the time for those below the 1 month.
  2. Nearly 3 months, weight loss ≥ 5%.
  3. Suffering from congenital heart disease, rheumatic heart disease, congestive heart failure, unstable angina, and had a myocardial infarction, percutaneous transluminal coronary angioplasty (PTCA) or off-line clinical significance of arrhythmia.
  4. Bilateral renal artery stenosis, solitary kidney, serum creatinine> 133μmol / L .
  5. Active liver disease, history of chronic persistent hepatitis, ALT> upper limit of normal.
  6. Peptic ulcer or malabsorption syndrome .
  7. With insulin-treated diabetes.
  8. There is a history of appetite or abuse of laxatives by hyperthyroidism.
  9. Pregnancy, pregnancy or breast-feeding women to prepare.
  10. For those who are allergic Chinese medicine, allergic people.
  11. Mentally ill.
  12. Hyperkalemia in patients.
  13. Cancer.
  14. Occurred within the past 6 months who had a stroke or transient ischemic attack (TIA).
  15. Nearly 3 months in patients receiving other clinical studies.
  16. Alcohol and / or psychoactive substances, drug abuse and dependency.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01082835

China, Beijing
Beijing Medical University ,Dongzhimen Hospital
Beijing, Beijing, China
Beijing Medical University,Dongfang Hospital
Beijing, Beijing, China
China Academy of Chinese Medical Sciences,Guang'anmen Hospital
Beijing, Beijing, China
Chinese Academy of Medical Sciences Fu Wai Cardiovascular Hospital
Beijing, Beijing, China
Capital University of Medical, Anzhen Hospital
Beijng, Beijing, China
Sponsors and Collaborators
Guang'anmen Hospital of China Academy of Chinese Medical Sciences
  More Information

Responsible Party: Guang'anmen Hospital, China Academy of Chinese Medical Sciences Identifier: NCT01082835     History of Changes
Other Study ID Numbers: 0081122 
Study First Received: March 8, 2010
Last Updated: March 15, 2010
Health Authority: China: Traditional Chinese Medicine Administration

Keywords provided by Guang'anmen Hospital of China Academy of Chinese Medical Sciences:
Chinese herbs

Additional relevant MeSH terms:
Metabolic Syndrome X
Vascular Diseases
Cardiovascular Diseases
Insulin Resistance
Glucose Metabolism Disorders
Metabolic Diseases
Antihypertensive Agents
Angiotensin II Type 1 Receptor Blockers
Angiotensin Receptor Antagonists
Molecular Mechanisms of Pharmacological Action processed this record on December 07, 2016